Pharmacological abnormalities in atopic dermatitis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Numerous investigations have described cutaneous and systemic physiological and pharmacological aberrations in atopic dermatitis and the atopic diathesis. Some of these studies set the stage for a focus upon cyclic nucleotide abnormalities. Elevated leukocyte cyclic AMP‐phosphodiesterase accounts for low intracellular cyclic AMP levels in atopic dermatitis. The resultant permissive effect correlates with abnormal functional parameters such as increased basophil histamine release and in vitro IgE synthesis. In vitro and clinical use of phosphodiesterase inhibitors corrects abnormal parameters and may indicate future therapeutic directions.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalAllergy
Volume44
DOIs
StatePublished - Jan 1 1989

Fingerprint

Atopic Dermatitis
Pharmacology
Phosphodiesterase Inhibitors
Basophils
Histamine Release
Cyclic Nucleotides
Disease Susceptibility
Cyclic AMP
Immunoglobulin E
Leukocytes
Skin
In Vitro Techniques
Therapeutics
Direction compound

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Pharmacological abnormalities in atopic dermatitis. / Hanifin, Jon.

In: Allergy, Vol. 44, 01.01.1989, p. 41-46.

Research output: Contribution to journalArticle

@article{7755ae82db74400ea04eb5ad2b1a972c,
title = "Pharmacological abnormalities in atopic dermatitis",
abstract = "Numerous investigations have described cutaneous and systemic physiological and pharmacological aberrations in atopic dermatitis and the atopic diathesis. Some of these studies set the stage for a focus upon cyclic nucleotide abnormalities. Elevated leukocyte cyclic AMP‐phosphodiesterase accounts for low intracellular cyclic AMP levels in atopic dermatitis. The resultant permissive effect correlates with abnormal functional parameters such as increased basophil histamine release and in vitro IgE synthesis. In vitro and clinical use of phosphodiesterase inhibitors corrects abnormal parameters and may indicate future therapeutic directions.",
author = "Jon Hanifin",
year = "1989",
month = "1",
day = "1",
doi = "10.1111/j.1398-9995.1989.tb02454.x",
language = "English (US)",
volume = "44",
pages = "41--46",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0108-1675",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Pharmacological abnormalities in atopic dermatitis

AU - Hanifin, Jon

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Numerous investigations have described cutaneous and systemic physiological and pharmacological aberrations in atopic dermatitis and the atopic diathesis. Some of these studies set the stage for a focus upon cyclic nucleotide abnormalities. Elevated leukocyte cyclic AMP‐phosphodiesterase accounts for low intracellular cyclic AMP levels in atopic dermatitis. The resultant permissive effect correlates with abnormal functional parameters such as increased basophil histamine release and in vitro IgE synthesis. In vitro and clinical use of phosphodiesterase inhibitors corrects abnormal parameters and may indicate future therapeutic directions.

AB - Numerous investigations have described cutaneous and systemic physiological and pharmacological aberrations in atopic dermatitis and the atopic diathesis. Some of these studies set the stage for a focus upon cyclic nucleotide abnormalities. Elevated leukocyte cyclic AMP‐phosphodiesterase accounts for low intracellular cyclic AMP levels in atopic dermatitis. The resultant permissive effect correlates with abnormal functional parameters such as increased basophil histamine release and in vitro IgE synthesis. In vitro and clinical use of phosphodiesterase inhibitors corrects abnormal parameters and may indicate future therapeutic directions.

UR - http://www.scopus.com/inward/record.url?scp=85047689991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047689991&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.1989.tb02454.x

DO - 10.1111/j.1398-9995.1989.tb02454.x

M3 - Article

C2 - 2479282

AN - SCOPUS:85047689991

VL - 44

SP - 41

EP - 46

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0108-1675

ER -